Análise de fatores preditivos para tumorigenese no câncer de pulmão

Abstract

The aim of this study was to evaluate the expression of biological markers (p53, ANXA1, EGFR, VEGF) in lung cancer patients: large cell carcinoma, squamous cell carcinoma and adenocarcinoma. Compared the control tissue with cancer cells, stronger staining of ANXA1 was observed in adenocarcinoma, squamous cell carcinoma and large-cell carcinoma. The analysis in ANXA1 posttranslation modification in lung cancer indicated that ANXA1-serine27- phosphorylation immunostaining in large-cell carcinoma was similar to control tissue, but was increased adenocarcinoma and squamous cell carcinoma. However, ANXA1-tyrosine21-phosphorylation immunoreactivity was detected with higher levels in the adenocarcinoma and squamous cell carcinoma and it was intensely detected I large-cell carcinoma. In the VEGF expression, it was significantly higher in adenocarcinoma, squamous cell carcinoma and large-cell carcinoma when compared with control tissue. About the p53, a stepwise increment of expression was found in the adenocarcinoma cells when compared to control tissue. A moderate to intense expression of p53 was shown to have a statistical significant increase in squamous cell carcinoma and large cell carcinoma. Finaly, EGFR immunohistochemical expression was significantly higher in cancer cells when compared with control tissue. In conclusion, we have identified potential candidates for biomarkers in lung adenocarcinoma, squamous cell carcinoma and large cell carcinoma. The proteins: ANXA1, EGFR, VEGF and p53 were found to be differentially expressed among lung cancer tissue. Also, the ANXA1 Tyr21 phosphorylation showed a closed relation with EGFR expression, which according to previous studies indicates an important mechanism in cell proliferation and differentiation. The correlation of those proteins during cell carcinogenesis need to be further validated. The present findings suggested that those proteins might be reliable biomarkers for prognosis of lung cancer. Our results reported here, combined with future studies, could have clinical value in predicting the prognosis of lung cancer, and identifying lung cancer patients that are at high risk of progression.